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Introduction
Oral leukoplakia is by far the most common oral 
premalignant lesion, representing 85% of such lesions. 
(Neville, 2002) Previous studies suggest that the malignant 
transformation potential of oral leukoplakia is 3~17%. 
(Silverman et al., 1984; Schepman et al., 1998). The 
criteria for determining the malignancy potential of oral 
leukoplakias are based on the presence and degree of 
epithelial dysplasia. However, more reliable indicators are 
needed because oral leukoplakias are mostly early lesions 
(mild and moderate epithelial dysplasia), and potential 
malignancies cannot be estimated by histopathologic 
assessment alone.
Various studies have been performed to find biomarkers 
of transforming oral premalignant lesions. One of them 
found genetic changes related to abnormal cells. The 
established methods of identifying these changes are 
array comparative genomic hybridization (aCGH), single 
nucleotide pleomorphism (SNP) array, and copy number 
assay. These can detect chromosomal anomalies in the 
specimen of the lesion. (Kallioniemi et al., 1992; Wang 
et al., 2007).
Copy number variations (CNVs) represent the copy 
number changes of DNA fragments, ranging from 1 
kilobase or more, resulting from duplication or deletion. 
1Yonsei Empathy Dental Clinic, Department of Oral & Maxillofacial Surgery, 2Oral Cancer Research Institute, 3College of Dentistry, 
Yonsei University, Seoul, Korea  *For correspondence: CHA8764@yuhs.ac
Abstract
 Background: The cancer progression of oral leukoplakia is an important watchpoint in the follow-up 
observation of the patients. However, potential malignancies of oral leukoplakia cannot be estimated by 
histopathologic assessment alone. We evaluated genetic abnormalities at the level of copy number variation 
(CNV) to investigate the risk for developing cancer in oral leukoplakias. Materials and Methods: The current 
study used 27 oral leukoplakias with histological evidence of dysplasia. The first group (progressing dysplasia) 
consisted of 7 oral lesions from patients with later progression to cancer at the same site. The other group (non-
progressing dysplasia) consisted of 20 lesions from patients with no occurrence of oral cancer and longitudinal 
follow up (>7 years). We extracted DNA from Formalin-Fixed Paraffin-Embedded (FFPE) samples and examined 
chromosomal loci and frequencies of CNVs using Taqman copy number assays. Results: CNV frequently occurred 
at 3p, 9p, and 13q loci in progressing dysplasia. Our results also indicate that CNV at multiple loci–in contrast to 
single locus occurrences–is characteristic of progressing dysplasia. Conclusions: This study suggests that genetic 
abnormalities of the true precancer demonstrate the progression risk which cannot be delineated by current 
histopathologic diagnosis. 
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(Feuk et al., 2006; Oh and Nishimura, 2008). CNVs 
can contribute significantly to genomic polymorphism. 
Therefore, CNVs at specific sites are thought to be disease 
causative or susceptive. (Feuk et al., 2006).
One of the best ways to ascertain the genetic changes 
related to oral cancer progression is to compare genetic 
sequences of progressing and nonprogressing oral lesions. 
The malignant transformations arise from alterations of 
crucial regulatory genes. Therefore, progressing lesions 
may differ from nonprogressing ones even when they are 
histopathologically similar.
We have examined genetic abnormalities in oral 
leukoplakia using copy number assay. Moreover, we 
have verified differences between progressing and 
nonprogressing oral leukoplakias in terms of these 
abnormalities. 
Materials and Methods
Sample collection 
This study used Formalin-Fixed Paraffin-Embedded 
(FFPE) from the Department of Oral Pathology, Yonsei 
University Dental College. All lesions were diagnosed 
as mild or moderate epithelial dysplasia. Lesions with 
severe epithelial dysplasia were excluded from this study 
because they were thought to be undergoing neoplastic 
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transformation. 
Two sample groups were used. The first group, termed 
nonprogressing lesion, consisted of oral leukoplakias from 
patients without progression to head and neck cancer. 
These samples included 20 patients with early epithelial 
dysplasia. 
The second group, termed progressing lesion, 
consisted of early epithelial dysplasia from 7 patients 
with progression to oral cancer. We confirmed that the 
preceding epithelial dysplasia and the following oral 
cancer occurred at identical sites using pathologic reports 
and medical records. In addition, we only included 
samples in which the onset of malignant lesions was more 
than 6 months since the onset of primary oral leukoplakias. 
All progressing lesions were confirmed by histopathologic 
diagnosis. 
The gender and age distribution of nonprogressing and 
progressing sample sets are shown in Table 1.
Paraffin block microdissection and DNA extraction
Ten 20mm-thick sections were collected from 27 
paraffin blocks using the microtome. We deparaffinized 
the 20 μm sections using xylene washes for DNA 
extraction, then washed them using ethanol. Next, we 
added proteinase to each tube and placed them in a 56℃ 
heat block. The samples were then incubated for 1 hour 
in 90℃ to reverse formalin crosslinking. 
CNV Analysis 
We carried out CNV analysis using genomic DNA 
(gDNA) from twenty-seven FFPE tissue samples. The 
assay was confined to the eight genomic regions listed in 
Table 2. The gDNA from each FFPE sample, Taqman copy 
number assay (Life Technologies Corporation, Carlsbad, 
CA, USA), and Taqman copy number reference assay 
(Life Technologies Corporation, Carlsbad, CA, USA) 
were mixed together in a single well and duplex real-time 
polymerase chain reaction (RT-PCR) was performed. We 
loaded the reaction plates using the 7900 HT PCR system 
(Life Technologies Corporation, Carlsbad, CA, USA).
The copy number assay amplifies the target gene 
and the reference assay amplifies a reference sequence 
that is known to exist in two copies in a diploid genome. 
This study used the ribonuclease P RNA component H1 
(H1RNA) gene (RPPH1) on chromosome 14, cytoband 
14q11.2 as reference sequence.
When each Taqman probe binds to its target gene, the 
dye (FAM or VIC) generates fluorescence. Otherwise, 
the proximity of the quencher dye to the fluorescent dye 
blocks the fluorescent signal. 
The copy number of the target sequence in each test 
sample is determined by relative quantitation (RQ) using 
the comparative cycle threshold (Ct) method, which 
measures the PCR cycles needed to obtain the intersection 
between threshold line and amplification curve. The 
greater the Ct value, the smaller the amount of DNA. 
(Figure 1).
This study measures the Ct difference (∆Ct) between 
Table 2. Taqman Copy Number Assay
Cytoband Gene symbol Gene name Assay location Gene function Assay ID  
9p21.3c CDKN2A cyclin-dependent kinase 
inhibitor 2A (melanoma, p16, 
inhibits CDK4)
chr9:21976994 CDK inhibitor Hs04367145_cn
chr9:21987690 Hs03717798_cn
11q13.3d CCND1 cyclin D1 chr11:69466166 Regulates CDK kinase Hs02666923_cn
chr11:69469088 Hs01978234_cn
17p13.1c TP53 tumor protein p53 chr17:7572767 Regulates cell division Hs02821479_cn
chr17:7578588 Hs06423639_cn
3p21.31a RASSF1 Ras association (RalGDS/AF-
6) domain family member 1
chr3:50367666 Multiple functions of 
tumor suppression
Hs02560777_cn
chr3:50370782 Hs03490926_cn
3p14.2c FHIT fragile histidine triad gene chr3:60249964 Diadenosine triphosphate 
hydrolase
Hs03499888_cn
chr3:60192696 Hs03469498_cn
8p21.3c LPL lipoprotein lipase chr8:19802042 Instructions for making an 
enzyme
Hs03689798_cn
chr8:19823926 Hs00778029_cn
18q21.2a SMAD4 SMAD family member 4 chr18:48568378 TGF-β TF Hs06436145_cn
chr18:48605262 Hs02599864_cn
13q14.2b RB1 retinoblastoma 1 chr13:48884045 Transcriptional repression; 
control of E2Fs
Hs07038675_cn
chr13:48938126 Hs06369868_cn
Table 1. Characteristics of Patients
Non-progressing 
epithelial dysplasia
Progressing 
epithelial dysplasia
Sex (male/female) 15/5 3/4
Mean age 52 62
Figure 1. Cycle Threshold (Ct). The x axis represents 
the number of cycles and the y axis represents an arbitrary 
fluorescence unit
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target and reference sequences, then compares the ∆Ct 
values of test samples to a calibrator sample known to 
have two copies of the target sequence. The Human 
Genomic DNA (Promega Corporation, Madison, WI, 
USA) was used as a reference sample having normal 
genetic information. 
After carrying out RT-PCR, we analyzed the results 
in terms of copy numbers using comparative Ct (∆∆Ct) 
relative quantitation analysis using CopyCaller software 
(Life Technologies Corporation, Carlsbad, CA, USA). To 
conceal the identities of the samples, groups were labeled 
alpha numerically for handling during DNA extraction and 
analysis for genetic anomalies.
Results 
Clinical impression
Characteristics of patients: Patients’ overall incidence 
age of oral leukoplakias was from 25 to 72 years old, the 
average age being 54.3 ± 12.6 years. The average age when 
the nonprogressing patients were first diagnosed with oral 
epithelial dysplasia is 51.7 ± 13.8 years old. The average 
age when the progressing patients were first diagnosed 
with oral epithelial dysplasia was 61.6 ± 1.3 years old. 
In the case of nonprogressing samples, the gender ratio 
was fifteen men and five women. In the case of progressing 
samples, the gender ratio was three men and four women. 
Follow-up observation period: The follow-up 
observation period for nonprogressing cases was 9.8 ± 
2.4 years on average, and at least 7 years. In progressing 
cases, the average period to onset of oral cancer was 43.0 
± 36.7 months from the time of diagnosis of oral epithelial 
dysplasia, with a 13-month minimum period of onset.
Distribution by site of occurrence: Of the 27 total 
samples of oral epithelial dysplasia, 12 cases occurred 
in tongue, 8 in buccal mucosa, 6 in gingival, and 1 case 
in the palate. Of these, malignant progression occurred 
in 4 cases in tongue, 2 in gingiva, and 1 case in buccal 
mucosa. (Tables 3, 4)
The frequency of CNV
Of the 27 oral epithelial dysplasias subjected to 
RT-PCR, four samples (patient numbers 1, 2, 5, and 
21) failed PCR amplification, apparently due to FFPE 
sample characteristics, insufficient DNA, and excessive 
fragmentation. 
CNV was revealed in 12 cases (52.2%) of the entire 
23 oral epithelial dysplasias on which CNV analysis 
was performed. The frequency of CNV was greater in 
progressing lesions. While all progressing lesions showed 
CNV at more than one site, only 42.9% of nonprogressing 
lesions showed any CNV.  Moreover, three or more CNVs 
appeared mainly in progressing lesions (66.7%), though 
infrequently in nonprogressing lesions (5.9%). Genetic 
changes in progressing lesions appeared, on average, at 3.3 
sites. However, those of nonprogressing lesions appeared, 
on average, at 2.0 sites. (Tables 5, 6)
Types of CNV
In all specimens, CNV appeared most frequently at 3p 
and 9p (32.6% and 17.4%, respectively). CNV of 3p was 
most common in nonprogressing lesions. CNVs of 3p, 
9p, and 13q appeared frequently in progressing lesions. 
In nonprogressing lesions, deletions in 3p14 and 3p21 
appeared in 29.4% and 23.5% of cases, respectively. In 
contrast, deletions in 3p14, 3p21, and 9p21 all appeared 
in 50% of progressing lesions.
In nonprogressing lesions, CNV of sites besides 3p 
were rare, CNV occurrences in 9p, 18q, and 17p totalling 
only 5.9%. The frequency of CNV occurrence in sites 
besides 3p was greater in progressing lesions, increasing 
Table 3. Non-progressing Epithelial Dysplasia
Patient 
number Age Sex Site
Follow-up 
(Year)
1 67 M Buccal mucosa 15
2 60 F Mn. Gingiva 14
3 52 M Mn. Gingiva 10
4 53 F Tongue 10
5 59 M Tongue 15
6 25 M Tongue 8
7 38 M Buccal mucosa 11
8 51 M Mx. Gingiva 11
9 57 M Tongue 10
10 24 M Palate 8
11 67 M Tongue 9
12 45 F Mx. Gingiva 9
13 57 M Buccal mucosa 7
14 40 M Tongue 7
15 53 M Buccal mucosa 8
16 68 M Buccal mucosa 9
17 62 F Buccal mucosa 8
18 72 F Tongue 9
19 50 M Buccal mucosa 12
20 34 M Tongue 8
Mx: maxilla, Mn: mandible, M: male, F: female
Table 4. Progressing Epithelial Dysplasia
Patient 
number Age Sex Site
Interval 
(Month)
21 64 M Buccal mucosa 45
22 61 M Tongue 17
23 62 F Mn. Gingiva 13
24 60 F Tongue 42
25 62 F Tongue 54
26 61 F Tongue 117
27 61 M Mn. Gingiva 13
Table 5. CNV in DNA from Epithelial Dysplasia
Nonprogressinga Progressinga pb
Number of 
samples
17 6
Number of 
samples with 
CNV
6 (35.3) 6 (100.0) 0.014
More than three 
CNVs
1 (5.9) 4 (66.7) 0.008
3p14 CNV 5 (29.4) 3 (50.0) 0.621
3p21 CNV 4 (23.5) 3 (50.0) 0.318
9p21 CNV 1 (5.9) 3 (50.0) 0.04
18q21 CNV 1 (5.9) 2 (33.3) 0.155
17p13 CNV 1 (5.9) 2 (33.3) 0.155
13q14 CNV 0 3 (50.0) 0.011
11q13 CNV 0 2 (33.3) 0.059
8q21 CNV 0 2 (33.3) 0.059
aThe values  in parentheses are percentages; bFisher’s exact test
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about eightfold (50%) in the case of 9p and about sixfold 
(33.3%) in the case of 18q and 17p. Furthermore, only 
progressing lesions manifest CNVs of 13q, 11q, and 8p. 
(Tables 5, 6)
Discussion
The risk of cancer progression increases in oral 
leukoplakia including erythematous or erosive lesion, 
or having verrucoid hyperplastic pattern, or showing 
epithelial dysplasia. (Silverman et al., 1984). In 
determining the treatment of oral leukoplakia, one must 
consider the risk of malignant transformation, size of the 
lesion, usefulness of the excision, and degree of patient 
cooperation. 
Since there is no clinical reference with which to 
separate the stages of oral leukoplakia nor standardized 
treatment, we cannot predict the effectiveness of surgical 
treatment. In addition, oral leukoplakia is difficult to 
treat since it occurs multiply, has variable features, and 
in many cases manifests no clear boundary. Moreover, it 
is difficult to treat based on histological evaluation alone, 
as it is impossible to accurately assess the prognosis of 
recurrence and malignant transformation. 
In recent years, researchers have sought a biomarker 
to predict the prognosis of oral leukoplakia. As molecular 
events indicate a tumor’s biological characteristics, it may 
be advantageous to base a prognosis on a molecular staging 
system rather than conventional clinicopathological 
features. (Partridge et al., 1999) Ideally, a genetic marker 
would yield information on protein, tissue, organization, 
and human body.
CNV is an important polymorphism that affects the 
expression of nearby genes or in the rearranged area. 
(Henrichsen et al., 2009) Normally, humans have two 
copies of each autosomal region. CNV might be caused 
by genomic rearrangement such as deletion, duplication, 
inversion, and translocation, producing a higher or 
lower level of transcription than in the case of a single 
replication. (Hastings et al., 2009). CNVs connect the 
gap between single-nucleotide change and microscopic 
chromosomal alteration in genetic changes. Since the 
finding of 21 trisomy in Down syndrome in 1959, many 
studies have drawn associations between CNV and 
genetic diseases such as cancer, immune disorders, and 
neurological disorders. 
Methods for CNV discovery fall into two main 
categories: genome-wide detection, of which array CGH 
is representative, and target-specific detection, based on 
the RT-PCR used in this study. As described above, when 
a specific probe is bound to the target gene and amplified 
through the process of PCR, it will show a constant signal. 
The copy number can be estimated by comparing the 
signal detected in test samples to controls. This method 
has two advantages: the high resolution of the desired 
target gene and the fact that a probe, once produced, can 
be used repeatedly in approximately 230 samples.
Many studies of head and neck cancer have observed 
a genomic imbalance, commonly in 3p, 8p, 9p, 11q, 
17p, and 13q. (Brennan et al., 1995; Choi et al., 2000; 
el-Naggar et al., 1993; Maestro et al., 1996; Martin et 
al., 2008; Partridge et al., 1999; Pateromichelakis et al., 
2000; Singh et al., 2013; van der Riet et al., 1994; Ye et 
al., 2007). Among these, modification of 3p occurs quite 
frequently in oral cancer. This chromosomal region is 
known to contain at least three tumor suppressor genes. 
(Maestro et al., 1993; Wu et al., 1994).
Studies of chromosomal abnormalities in oral 
precancerous lesions are ongoing. Mao et al. first studied 
chromosomal abnormalities in the oral leukoplakia, 
investigating the loss of 3p14 and 9p21 regions and 
finding that oral cancer was more likely to migrate when 
these sites were deficient (Mao et al., 1996). Partridge et 
al. studied allelic imbalances in the 3p21, 8p21-23, 9p21, 
13q14.2, 17p13.1, and 18q21.1 regions. (Partridge et al., 
1998). They established that the likelihood of progressive 
Table 6. Summary of CNV Findings for All Samples
Sample number 3p14.2 3p21.31 9p21.3 18q21.2 17p13.1 13q14.2 11q13.3 8p21.3
Non-progressing epithelial dysplasia
3 +
4
6
7 + +
8
9
10 +
11
12
13
14 + + + +
15 + +
16
17 + +
18
19
20
Progressing epithelial dysplasia
22 + + + + + +
23 +
24 - - - -
25 -
26 + + +
27 + + + + +
+: copy number gain, -: copy number loss
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squamous cell carcinoma is very large in lesions with an 
imbalance in two or more fields. Rosin et al. investigated 
sites of chromosomal deletion in patients with early 
oral premalignant lesions and confirmed that the risk of 
malignant transformation increased when chromosomal 
deletion appears not only at 3p and 9p, but also 4q, 8p, 
11q, and 17p. (Rosin et al., 2000). Garnis et al. performed 
aCGH on oral premalignant lesions and squamous cell 
carcinomas, confirming that the genetic changes of mild 
epithelial dysplasia that has migrated to oral cancer are 
similar to those in severe lesions. (Garnis et al., 2009). 
This phenomenon contrasts with the histopathological 
similarity of progressing and nonprogressing epithelial 
dysplasia. In the study of Garnis et al. (2009) the frequent 
chromosomal deformation in progressing epithelial 
dysplasia involved 9p, 8q, 20p, and 20q.
We studied differences between CNVs in 
nonprogressing and progressing lesions using the Taqman 
copy number assay. CNV of 3p was most frequent in both 
progressing (50.0%) and nonprogressing (26.5%) lesions. 
Accordingly, we could confirm the results of previous 
studies that CNV of 3p reflects an important genetic 
imbalance related to epithelial changes. (Califano et al., 
1996; Emilion et al., 1996; Mao et al., 1996; Partridge 
et al., 1998; Rosin et al., 2000). Also, similar to findings 
in a previous study, multiple CNVs of specific sites (3p, 
9p, 13q, 18q, 17p, 11q, and 8p) in progressing lesions 
appeared more frequently than nonprogressing ones. 
Therefore, multiple genetic changes at those sites are 
considered indicators of progressing epithelial dysplasia. 
(Partridge et al., 1998).
In terms of the frequency of genetic variations, the 
results of the current study differ from those of previous 
studies. Hwang et al. found expression of p53 (17p13) 
in 29% of nonprogressing cases and 43% of progressing 
cases.(Jin Ha et al., 2002) However, this study found 5.9% 
and 33.3%, respectively. Moreover, Baek et al. studied the 
expression of cyclin D1 (11q13) and reported its presence 
in 20% of nonprogressing cases and 80% of progressing 
cases. (Ji Young et al., 2001) However, the current study 
found it in 0% and 33% of cases, respectively. According 
to the study by Rosin et al., allelic loss of 3p was found in 
25% of nonprogressing lesions and 64% of progressing 
lesions, and in the case of 9p, 46% and 83%, respectively. 
(Rosin et al., 2000) In contrast, this study observed CNV 
of 3p in 26.5% of nonprogressing lesions and 50.0% of 
progressing lesions; CNV of 9p was observed in 5.9% 
and 50.0%, respectively. Moreover, this study differed 
from that of Garnis et al. in terms of the frequency of 
genetic changes at sites 3p and 9p. (Garnis et al., 2009). 
These differences may be attributed to small sample 
sizes, disparate methods for defining and classifying oral 
premalignant lesions, and different analytical approaches. 
As confirmed in this study, genetic changes at 3p 
and 9p regions are involved in early cancer progression. 
(el-Naggar et al., 1995; Califano et al., 1996). In 
addition, depending on the histological stages from oral 
precancerous lesions to head and neck cancer, loss of 
heterozygosity and microsatellite instability increase. 
(Rosin et al., 2000; Ha et al., 2002; Garnis et al., 2009). 
However, we should keep in mind that progression 
of cancer depends on a tight web of interactions and 
that various genetic changes in lesions may appear 
simultaneously. We cannot make an absolute equation 
between specific genetic changes and the phases of lesion 
progression. The genetic abnormalities revealed in this 
study may occur elsewhere than in epithelial dysplasia 
and carcinoma in situ.
In conclusion, verifying chromosomal changes in 
several regions, including 3p and 9p in patients with oral 
premalignant lesions, may help in evaluating the risk of 
malignant transformation. If we combine progression 
risk factors based on the conventional classification 
system with those based on genetic imbalances, we may 
better understand the potential risk of oral leukoplakia 
progressing to malignancy and establish a strategy to 
improve the prognosis and clinical course.
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